CVS HEALTH CORPORATION $1,500,000,000 5.000% Senior Notes due 2026 $1,500,000,000 5.125% Senior Notes due 2030 $1,750,000,000 5.250% Senior Notes due 2033 $1,250,000,000 5.625% Senior Notes due 2053 Underwriting AgreementSignificant Subsidiaries • February 15th, 2023 • CVS HEALTH Corp • Retail-drug stores and proprietary stores • New York
CVS Health Corporation, a Delaware corporation (the “Company”), proposes to issue and sell $1,500,000,000 aggregate principal amount of its 5.000% Senior Notes due 2026 (the “2026 Notes”), $1,500,000,000 aggregate principal amount of its 5.125% Senior Notes due 2030 (the “2030 Notes”), $1,750,000,000 aggregate principal amount of its 5.250% Senior Notes due 2033 (the “2033 Notes”) and $1,250,000,000 aggregate principal amount of its 5.625% Senior Notes due 2053 (the “2053 Notes” and together with the 2026 Notes, the 2030 Notes and the 2033 Notes, the “Notes”) to the several underwriters named on Schedule I hereto (the “Underwriters”), for which BofA Securities, Inc., Barclays Capital Inc., and J.P. Morgan Securities LLC are acting as representatives (the “Representatives”). The Notes will (a) have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in Section 1(a) hereof) and (b) b
